REVIEW
Characteristics, management and outcome of hospitalized patients with interstitial lung disease in Greece
 
More details
Hide details
1
6th Pulmonary Clinic, Sotiria Chest Diseases Hospital, Athens, Greece
 
2
5th Pulmonary Clinic, Sotiria Chest Diseases Hospital, Athens, Greece
 
3
Radiology Department, Sotiria Chest Diseases Hospital, Athens, Greece
 
 
Corresponding author
 Michail Toumbis   

152 Mesogion Ave., 11527 Athens
 
 
Pneumon 2015;28(2):154-160
 
KEYWORDS
ABSTRACT
Aim:
To investigate retrospectively patients’ characteristics, reason of admission, medical management and outcome of hospitalized patients with interstitial lung disease (ILD) within the years before the establishment of the latest guidelines and subsequently to reassess their diagnosis with respect to the novel international recommendations.

Methods:
Medical records of patients who were hospitalized in the 1st and 6th pulmonary department of Sotiria chest hospital and diagnosed with ILD within the years 1992-2008 were retrieved and analysed.

Results:
Seventy files were found suitable. There were 36 men and 34 women with a mean age of 67.4±13.7 years, most of them being non smokers. An underlying aetiologic condition was identified in 16 patients (22.8%). Only 8 patients (11.4%) had already undergone or were referred for a surgical lung biopsy. For 29 patients (41%) lung function data were found in files. The most common reasons for admission were dyspnea and fever. Αcute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) was the most frequent cause of inhospital mortality. Subacute deterioration of ILD, first investigation and acute exacerbation most often led to hospitalization. Unclassifiable ILD was the diagnosis at discharge in most cases. In almost half of the cases an alternative diagnosis occurred after re-examination of files.

Conclusion:
The implementation of the novel international recommendations regarding ILD in combination with the multidisciplinary approach led to an alternative diagnosis in almost half of the patients with ILD. A new prospective registry concerning ILD epidemiology, diagnosis, management and treatment is necessary in Greece.

ABBREVIATIONS
AE-IPF: acute exacerbation of idiopathic pulmonary fibrosis, ALI: acute lung injury, ANA: antinuclear antibodies, ARDS: acute respiratory distress syndrome, BAL: bronchoalveolar lavage, COP: cryptogenic organizing pneumonia, CPFE: combined pulmonary fibrosis and emphysema, CTD: connective tissue disease, DLCO: diffusing capacity for carbon monoxide, HP: hypersensitivity pneumonitis, HRCT: high resolution computed tomography, ICU: intensive care unit, IIP: idiopathic interstitial pneumonia, ILD: interstitial lung disease, IPF: idiopathic pulmonary fibrosis, MRC: medical research council, NSIP: non-specific interstitial pneumonia, SD: standard deviation, TLC: total lung capacity, UIP: usual interstitial pneumonia
CONFLICTS OF INTEREST
The authors have indicated no financial conflicts of interest.
 
REFERENCES (30)
1.
Wells AU, Hirani N and on behalf of the BTS Group, a subgroup of the British Thoracic Society Standards of Care Committee, in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Interstitial lung disease guideline. Thorax 2008;63:v1-v58.
 
2.
Coultas DB, Zumwalt RE, Black WC, et al. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 1994;150:967-72.
 
3.
American Thoracic Society/European Respiratory Society. International Multidisciplinary Consensus Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2002;165:277-304.
 
4.
Travis WD, Costabel U, Hansell DM, et al. An Official American Thoracic Society/European Respiratory Society Statement: Update of the International Multidisciplinary Classification of the Idiopathic Interstitial Pneumonias. Am J Respir Crit Care Med 2013;188:733-48.
 
5.
Raghu G, Collard HR, Egan JJ, et al. ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788-824.
 
6.
Lee AS, Mira-Avendano I, Ryu JH, et al. The burden of idiopathic pulmonary fibrosis: an unmet public health need. Respir Med 2014;108:955-67.
 
7.
Navaratnam V, Fogarty AW, Glendening R, et al. The increasing secondary care burden of idiopathic pulmonary fibrosis: hospital admission trends in England from 1998 to 2010. Chest 2013;143:1078-84.
 
8.
American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 2000;161:646-64.
 
9.
Latsi PI, du Bois RM, Nicholson AG, et al. Fibrotic idiopathic interstitial pneumonia: The prognostic value of longitudinal functional trends. Am J Respir Crit Care Med 2003;168:531-7.
 
10.
Collard HR, King TE Jr, Bartelson BB, et al. Changes in clinical and physiologic variables predict survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2003;168:538-42.
 
11.
Nathan SD, Meyer KC. IPF clinical trial design and endpoints. Curr Opin Pulm Med 2014;20:463-71.
 
12.
Fishman A, Elias J, Fishman J, et al. Idiopathic Pulmonary Fibrosis. In: Fishman AP. Fishman’s Pulmonary Diseases and Disorders. Vol 1. 4th ed. The McGraw-Hill Companies, Inc.; 2008:1143-60.
 
13.
Fischer A, Pfalzgraf FJ, Feghali-Bostwick CA, et al. Anti-th/topositivity in a cohort of patients with idiopathic pulmonary fibrosis. J Rheumatol 2006;33:1600-5.
 
14.
Vij R, Noth I, Strek ME. Autoimmune-Featured Interstitial Lung Disease: A Distinct Entity. Chest 2011;140:1292-9.
 
15.
Raghu G, Anstrom KJ, King TE Jr, et al. Idiopathic Pulmonary Fibrosis Clinical Research Network. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med 2012;366:1968-77.
 
16.
Sato T, Teramukai S, Kondo H, et al; Japanese Association for Chest Surgery. Impact and predictors of acute exacerbation of interstitial lung diseases after pulmonary resection for lung cancer. J Thorac Cardiovasc Surg 2014;147:1604-11.
 
17.
Ley B, Collard HR, King Jr TE. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:431-40.
 
18.
Papiris SA, Manali ED, Kolilekas L, et al. IPF exacerbations: Unravelling Ariadne’s thread. Crit. Care 2010;14:246.
 
19.
Kim DS, Park JH, Park BK, et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006;27:143-50.
 
20.
Crowley SP, Kelly P, Egan JJ. Acute exacerbations in idiopathic pulmonary fibrosis. Ann Intern Med 2006;144:218-9.
 
21.
Collard HR, Moore BB, Flaherty KR, et al; Idiopathic Pulmonary Fibrosis Clinical Research Network Investigators: Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636-43.
 
22.
Blivet S, Philit F, Sab JM, et al. Outcome of patients with idiopathic pulmonary fibrosis admitted to the ICU for respiratory failure. Chest 2001;120:209-12.
 
23.
Stern JB, Mal H, Groussard O, et al. Prognosis of patients with advanced idiopathic pulmonary fibrosis requiring mechanical ventilation for acute respiratory failure. Chest2001;120:213-9.
 
24.
Fumeaux T, Rothmeier C, Jolliet P. Outcome of mechanical ventilation for acute respiratory failure in patients with pulmonary fibrosis. Intensive Care Med 2001;27:1868-74.
 
25.
Cottin V, Nunes H, Brillet PY, et al. Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J 2005;26:586-93.
 
26.
Papiris SA, Triantafillidou C, Manali ED, et al. Combined pulmonary fibrosis and emphysema. Expert Rev Respir Med 2013;7:19-31.
 
27.
Lacasse Y, Girard M, Cormier Y. Recent advances in hypersensitivity pneumonitis. Chest 2012;142:208-17.
 
28.
Thomeer MJ, Costabel U, Rizzato G, et al. Comparison of registries of interstitial lung diseases in three European countries. Eur Respir J Suppl 2001;32:114-8.
 
29.
Karakatsani A, Papakosta D, Rapti A, et al; Hellenic Interstitial Lung Diseases Group. Epidemiology of interstitial lung diseases in Greece. Respir Med 2009;103:1122-9.
 
30.
Morell F, Villar A, Montero MÁ, et al. Chronic hypersensitivity pneumonitis in patients diagnosed with idiopathic pulmonary fibrosis: a prospective case-cohort study. Lancet Respir Med 2013;1:685-94.
 
eISSN:1791-4914
ISSN:1105-848X
Journals System - logo
Scroll to top